saterinone has been researched along with Heart Failure in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, G; Eichner, E; Iven, H; Kieback, AG; Ruckdeschel, W; Stolzenburg, K | 1 |
| Brouwer, J; Lahiri, A; Lie, KI; Mitrovic, V; Stolzenburg, K; Szabó, BM; van Dijk, RB; van Veldhuisen, DJ | 1 |
| Baumann, G; Iven, H; Kieback, AG; Stolzenburg, K | 1 |
| Böhm, M; Erdmann, E; Schwinger, RH; Ungerer, M | 1 |
2 trial(s) available for saterinone and Heart Failure
| Article | Year |
|---|---|
Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure.
Topics: Aged; Autonomic Nervous System; Double-Blind Method; Electrocardiography; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Injections, Intravenous; Male; Middle Aged; Neurotransmitter Agents; Phosphodiesterase Inhibitors; Piperazines; Pyridones | 1997 |
Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
Topics: Adult; Aged; Antihypertensive Agents; Cardiotonic Agents; Catheterization, Swan-Ganz; Dobutamine; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Nitroprusside; Oxygen Consumption; Phosphodiesterase Inhibitors; Piperazines; Pyridones | 1998 |
2 other study(ies) available for saterinone and Heart Failure
| Article | Year |
|---|---|
Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Blood Platelets; Blood Pressure; Chronic Disease; Creatine Kinase; Creatinine; Cyclic Nucleotide Phosphodiesterases, Type 3; Diastole; Heart Atria; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Pyridones; Statistics as Topic; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vascular Resistance | 2003 |
Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.
Topics: Adult; Binding, Competitive; Cardiotonic Agents; Electric Stimulation; Guanylyl Imidodiphosphate; Heart; Heart Failure; Humans; Imidazoles; In Vitro Techniques; Membranes; Milrinone; Myocardium; Piperazines; Pyridazines; Pyridones; Quinuclidinyl Benzilate; Receptors, Cholinergic; Receptors, Purinergic; Xanthines | 1990 |